Heron Therapeutics (HRTX) Non-Current Debt (2016 - 2026)
Heron Therapeutics' (HRTX) quarterly Non-Current Debt came in at $108.3 million in Q1 2026, up 329.57% YoY from $25.2 million in Q1 2025, and little changed on a QoQ basis from $107.9 million in Q4 2025.
Heron Therapeutics (HRTX) Non-Current Debt (2016 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 6 years of Non-Current Debt data on file, last reported at $108.3 million in Q1 2026.
- Quarterly Non-Current Debt rose 329.57% year-over-year to $108.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $108.3 million (up 329.57% YoY) and the FY2025 annual result came in at $107.9 million, up 331.15% from the prior year.
- Non-Current Debt held at $108.3 million in Q1 2026, from $107.9 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $108.3 million in Q1 2026 to a low of $24.0 million in Q3 2023.
- A 4-year average of $49.6 million and a median of $24.9 million in 2024 frame the typical range for Non-Current Debt.
- The widest YoY moves for Non-Current Debt: up 332.93% in 2025, down 3.13% in 2025.
- Tracing HRTX's Non-Current Debt over 4 years: stood at $24.3 million in 2023, then grew by 3.14% to $25.0 million in 2024, then jumped by 331.15% to $107.9 million in 2025, then gained by 0.38% to $108.3 million in 2026.
- The last three Non-Current Debt figures came in at $108.3 million (Q1 2026), $107.9 million (Q4 2025), and $107.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 108.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.73 Mn |
| Mar 31, 2026 | 108.31 Mn |
| Dec 31, 2025 | 107.90 Mn |
| Sep 30, 2025 | 107.49 Mn |
| Mar 31, 2025 | 25.21 Mn |
| Dec 31, 2024 | 25.03 Mn |
| Sep 30, 2024 | 24.83 Mn |
| Jun 30, 2024 | 24.63 Mn |
| Mar 31, 2024 | 24.45 Mn |
| Dec 31, 2023 | 24.26 Mn |
| Sep 30, 2023 | 24.02 Mn |
| Dec 31, 2017 | 25.00 Mn |
| Sep 30, 2017 | 25.00 Mn |
| Jun 30, 2017 | 25.00 Mn |
| Mar 31, 2017 | 50.00 Mn |
| Dec 31, 2016 | 50.00 Mn |
| Sep 30, 2016 | 50.00 Mn |